Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression

Cancer

Volumn 117, Issue 6, 2011, Pages 1172-1182

  Anees, Mariam ^a   Horak, Peter ^a   El Gazzar, Ahmed ^a   Susani, Martin ^a   Heinze, Georg ^a   Perco, Paul ^b   Loda, Massimo ^c   Lis, Rosina ^c   Krainer, Michael ^a   Oh, William K ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

death receptors; Prostate cancer; recurrence free survival; tumor necrosis factor related apoptosis inducing ligand (TRAIL)

Indexed keywords

DEATH RECEPTOR; FLICE INHIBITORY PROTEIN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STROMA; TUMOR MICROENVIRONMENT;

CARCINOMA; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, DEATH DOMAIN; RECURRENCE; STROMAL CELLS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 79952408952     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25504     Document Type: Article

References (45)

1. Parkin DM, Bray FI, Devesa SS., Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 (Suppl 8): S4-66.
2. Rubin MA, De Marzo AM,. Molecular genetics of human prostate cancer. Mod Pathol. 2004; 17: 380-388. (Pubitemid 41646614)
3. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer. 2005; 116: 174-181. (Pubitemid 40967252)
4. Jeronimo C, Henrique R, Campos PF, Oliveira J, Caballero OL, Lopes C, et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol. 2003; 56: 52-55. (Pubitemid 36132475)
5. Li LC, Carroll PR, Dahiya R., Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005; 97: 103-115. (Pubitemid 40277090)
6. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet. 2001; 10: 1413-1419. (Pubitemid 32640670)
7. Foley R, Hollywood D, Lawler M., Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer. 2004; 11: 477-488. (Pubitemid 39331278)
8. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC., Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169: 517-523. (Pubitemid 36132976)
9. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. (Pubitemid 39315317)
10. Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, et al. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res. 2007; 13: 6056-6063. (Pubitemid 350075062)
11. Ashkenazi A., Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2: 420-430. (Pubitemid 37328939)
12. Bucur O, Ray S, Bucur MC, Almasan A., APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci. 2006; 11: 1549-1568. (Pubitemid 43253441)
13. Nicholson DW., From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000; 407: 810-816.
14. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE., Targeting death receptors in bladder, prostate and renal cancer. J Urol. 2006; 175: 432-438. (Pubitemid 43067319)
15. Safa AR, Day TW, Wu CH., Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets. 2008; 8: 37-46. (Pubitemid 351237908)
16. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997; 91: 479-489. (Pubitemid 27508237)
17. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X., Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998; 94: 481-490. (Pubitemid 28391864)
18. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B., Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998; 188: 2375-2380. (Pubitemid 29028510)
19. Zitvogel L, Tesniere A, Kroemer G., Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006; 6: 715-727. (Pubitemid 44453458)
20. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B., Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol. 2007; 179: 5441-5453.
21. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A. 2001; 98: 11515-11520. (Pubitemid 32928760)
22. Ochsenbein AF., Immunological ignorance of solid tumors. Springer Semin Immunopathol. 2005; 27: 19-35. (Pubitemid 40905060)
23. Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 2005; 3: 335-343. (Pubitemid 40905625)
24. Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res. 2005; 11 (24 Pt 1): 8585-8591. (Pubitemid 43005904)
25. Wajant H., Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy. Mol Interv. 2003; 3: 124-127.
26. Kaplan EL MP,. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
27. Cox D., Regression models and life-tables (with discussion). J R Stat Soc Ser B. 1972; 34: 187-220.
28. Moon C, Park JC, Chae YK, Yun JH, Kim S., Current status of experimental therapeutics for prostate cancer. Cancer Lett. 2008; 266: 116-134.
29. Khan MA, Partin AW., Tissue microarrays in prostate cancer research. Rev Urol. 2004; 6: 44-46.
30. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR., Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002; 8: 2912-2923. (Pubitemid 35025739)
31. Dean JP, Nelson PS., Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer. 2008; 98: 245-249. (Pubitemid 351161233)
32. Risbridger GP, Taylor RA., Minireview: regulation of prostatic stem cells by stromal niche in health and disease. Endocrinology. 2008; 149: 4303-4306.
33. Cunha GR, Hayward SW, Wang YZ, Ricke WA., Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003; 107: 1-10. (Pubitemid 37100079)
34. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS., The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006; 66: 794-802. (Pubitemid 43165944)
35. Begley L, Keeney D, Beheshti B, Squire JA, Kant R, Chaib H, et al. Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes Cancer. 2006; 45: 136-146. (Pubitemid 43191020)
36. Thorburn A., Death receptor-induced cell killing. Cell Signal. 2004; 16: 139-144. (Pubitemid 37431163)
37. Schuler M, Green DR., Transcription, apoptosis and p53: catch-22. Trends Genet. 2005; 21: 182-187. (Pubitemid 40269857)
38. Wu GS, Burns TF, McDonald ER, 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997; 17: 141-143.
39. Graham B, Gibson SB., The two faces of NFkappaB in cell survival responses. Cell Cycle. 2005; 4: 1342-1345. (Pubitemid 41437117)
40. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, et al. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene. 2001; 20: 571-580. (Pubitemid 32156181)
41. Gerondakis S, Strasser A., The role of Rel/NF-kappaB transcription factors in B lymphocyte survival. Semin Immunol. 2003; 15: 159-166. (Pubitemid 38155822)
42. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J., NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol. 2001; 21: 5299-5305. (Pubitemid 32702435)
43. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol. 2004; 24: 8541-8555. (Pubitemid 39245075)
44. Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC, et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem. 2004; 279: 1513-1525. (Pubitemid 38082681)
45. Xu DD, Sun SD, Wang F, Sun L, Stackhouse D, Polascik T, et al. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology. 2009; 74: 654-658.